Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China중국에서 백신이 출시되는 동안 젊은 인구에 대한 COVID-19 부담의 전환 평가Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] absence Admissions age Assessing cause children China Chinese coronavirus disease Coronavirus disease 2019 Coverage COVID-19 deaths decrease Delta delta variant disease Effectiveness effort eligible Epidemics fatality groups highlight Hospitalization hospitalizations incidence include individual Infants Infection intensive care lineages novel Novel coronavirus novel coronavirus disease Novel coronavirus disease 2019 Older age over SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 transmission symptomatic infection symptomatic infections target population transition transition of disease burden Transmission triggered vaccinated against COVID-19 vaccination vaccination. Vaccine widespread [DOI] 10.1080/22221751.2022.2063073 PMC 바로가기 [Article Type] Article
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern우려되는 SARS-CoV-2 변이체에 대한 백신 효능 연구 진행Review Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition caused contributed coronavirus COVID-19 COVID-19 vaccine declined Delta Efficacy Epidemic epidemic wave Epidemics Health Organization Immune escape Measures Neutralizing Neutralizing antibodies omicron Omicron variants pathogenicity Prevention and control Protective Research research and development SARS-CoV-2 SARS-CoV-2 variant severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 triggered vaccination Vaccine vaccine efficacy variant Variant of concern. variants variety VoC VOCs WHO World Health Organization [DOI] 10.1080/21645515.2022.2057161 PMC 바로가기 [Article Type] Review
Atypical hemolytic uremic syndrome induced by SARS-CoV2 infection in infants with EXOSC3 mutationArticle Published on 2022-11-012022-11-16 Journal: Pediatric Nephrology (Berlin, Germany) [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] Activation affected aHUS. Atypical autosomal-recessive changes in characterized complement Complication COVID-19 Degradation disease disorder dysfunction endothelial cell damage EXOSC3 EXOSC3 mutation genetic disorder Infant Infection kidney mechanism microvascular injury Mutation neurodegenerative nuclear offset Pathogenesis Patient patients rare disease reported resulting RNA RNA exosome SARS-COV-2 infection SARS-CoV2 infection severe COVID-19 the SARS-CoV-2 thrombotic Treatment triggered uremic syndrome Viral RNA [DOI] 10.1007/s00467-022-05566-6 PMC 바로가기
COVID-19: Vaccines and therapeuticsArticle Published on 2022-11-012022-11-16 Journal: Bioorganic & medicinal chemistry letters [Category] SARS, 변종, [키워드] acute respiratory syndrome approved communicable coronavirus Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 therapeutics COVID-19 vaccines death deaths disease effective Health highlight Infection Measures New New variants of SARS-CoV-2 Protective reported Research SARS-CoV-2 SARS-CoV-2. Therapeutic strategies Treatment triggered Vaccine variant virus [DOI] 10.1016/j.bmcl.2022.128987 PMC 바로가기
A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in catsSARS-CoV-2의 스파이크 단백질을 기반으로 하는 서브유닛 백신 후보는 고양이의 감염성 바이러스 발산을 방지합니다Article Published on 2022-11-012022-09-11 Journal: Research in veterinary science [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affected cats demonstrated described effective human infection Infection Infectious virus Neutralizing antibody response occurred Oropharyngeal Population Prevent preventive measure preventive measures produced Protein rectal swab SARS-CoV-2 SARS-CoV-2 virus spike Spike protein submitted subunit Subunit vaccine Subunit vaccine. susceptible the disease the SARS-CoV-2 virus the Spike Transmission Trial triggered vaccination Vaccine vaccine candidate Viral viral infection virus [DOI] 10.1016/j.rvsc.2022.05.003 PMC 바로가기 [Article Type] Article
SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19Article Published on 2022-11-012022-11-15 Journal: Cell Reports [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] accompanied acute respiratory syndrome astrocytes Brain cellular mechanism CNS coronavirus coronavirus disease COVID-19 CP: Microbiology CP: Neuroscience Diabetic exacerbated High-resolution induce infect Infection initial investigated macaque microglia Microscopy modulated molecular Neuroinflammation Neurological complication Neurological complications Neuron neuronal neurotropism NHP non-human primate model olfactory patients plethora provide reducing Region rhesus rhesus. robust SARS-CoV-2 systemic inflammatory response triggered [DOI] 10.1016/j.celrep.2022.111573 PMC 바로가기
Nitazoxanide and COVID-19: A reviewArticle Published on 2022-11-012022-11-15 Journal: Molecular biology reports [Category] SARS, 치료제, [키워드] Activation acute lung injury acute respiratory distress acute respiratory distress syndrome addition Anti-inflammatory anti-parasitic drug anti-SARS-CoV-2 Antiviral antiviral activity antiviral property ARDS autophagic cause cell death clinical trial Coronavirus disease 2019 COVID-19 Cytokine storm Cytokines distress drug effective finding IFN immunological in silico in vitro study Infection inflammatory disorders inflammatory reaction inhibit Innate immunity interferon lung mammalian mitigate Multi-organ damage nitazoxanide oxidative stress pathogenesis of SARS-CoV-2 pro-inflammatory cytokines pro-inflammatory cytokines. Prospective Study Protozoa Rapamycin reduce Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 infections severe cases syndrome therapy Treatment triggered viral infections Viral pneumonia [DOI] 10.1007/s11033-022-07822-2 PMC 바로가기
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its borderArticle Published on 2022-10-292022-11-16 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] Community explained genomes Genomic surveillance growth advantage Infection International lineages New omicron onward transmission Outbreaks provide SARS-CoV-2 SARS-CoV-2 lineage significant level tracing Transmission Travel triggered variant [DOI] 10.1038/s41467-022-34186-9 PMC 바로가기
Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndromeArticle Published on 2022-10-202022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] analyzed Anti-viral anti-viral antibody antibody Antibody Response baseline chronic disease CMV cohorts COVID-19 EBV elevated fatigue healthy donor herpesvirus herpesvirus reactivation HERV HERV-K HHV6A HSV2 IgG immunoassay latent virus majority ME/CFS mechanisms multiplex myalgic encephalomyelitis/chronic fatigue syndrome. nuclear oral mucosa overlap Patient plasma Post-viral fatigue Reactivation retrovirus risk factor Saliva SARS-COV-2 infection shown significantly sustained Symptom syndrome systemically triggered unique viral infection virus virus [DOI] 10.3389/fimmu.2022.949787 PMC 바로가기
Learning from the COVID-19 pandemic for future epidemics and pandemics preparedness and response in Guinea: Findings from a scoping reviewArticle Published on 2022-10-172022-11-16 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] activities Analysis anticipated applied boost conducted counterproductive country COVID-19 COVID-19 pandemic database distress Epidemic Epidemics epidemiological finding FIVE generate globe Guinea health system health system preparedness and response implementation IMPROVE information learning measure Measures mechanism media National Novel coronavirus outbreak pandemic Pandemics policy decisions provide Research Resilience Resilience. responses SARS-CoV-2 These data triggered vaccination variant [DOI] 10.3389/fpubh.2022.879850 PMC 바로가기